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Obstructive sleep apnea syndrome (OSAS) is associated with recurrent nocturnal hypoxia during sleep; this hypoxia
has been implicated in the pathogenesis of cardiovascular complication. However, a useful soluble factor that is
sensitively correlated with OSAS severity for the diagnosis remains unidentified. We hypothesized that systemic
levels of basic fibroblast growth factor (bFGF), a hypoxia-induced cytokine, were affected by nocturnal hypoxemia
in OSAS patients, and we assessed whether the degree of change in the plasma bFGF concentrations before and
after nocturnal hypoxia is correlated with the severity of OSAS. Thirty subjects who had suspected OSAS and had
been investigated by nocturnal polysomnography (PSG) were enrolled. Plasma bFGF and vascular endothelial
growth factor (VEGF) concentrations the night before PSG and the next morning were measured by sandwich
enzyme-linked immunosorbent assay. Correlations between the changes in these factors and hypoxia-associated
parameters for OSAS severity were analyzed. Patients with OSAS had significantly elevated levels of plasma bFGF
but not VEGF and hemoglobin after rising. The degree of change in bFGF concentrations after nocturnal apnea
episodes was significantly correlated with diagnostic parameters for OSAS severity. The change in plasma bFGF
levels is associated with the degree of hypoxic state in OSAS patients, implying that bFGF might be a useful soluble
factor for evaluating OSAS severity.
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Obstructive sleep apnea syndrome (OSAS), which is a
common public health issue affecting as much as 4% of
the adult population, is associated with recurrent hyp-
oxia during sleep (Young et al. 1993; Strollo and Robers
1996). Patients with OSAS are exposed to decreased
oxygen saturation by repeated episodes of apnea and
hypopnea. The oxygen desaturation events result in the
development or exacerbation of cardiovascular, cerebro-
vascular, and metabolic diseases (Peppard et al. 2000;
Bradley and Floras 2009; Nishibayashi et al. 2008;
Vgontzas et al. 2000; Marin et al. 2005). Hypoxia and the
subsequent tissue ischemia are major pathophysiological* Correspondence: yumi_h_mail_1013@hotmail.co.jp; mk-satoh@md.tsukuba.
ac.jp
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Increased angiogenesis rates and the elevation of
hemoglobin (Hb) levels in response to hypoxia are part
of an adaptive response aimed at achieving increased de-
livery of oxygen and nutrients to the tissues (Bunn and
Poyton 1996; Bicknell and Harris 2004).
On a per-cell basis in hypoxic tissues, the transcrip-
tional response of mammalian cells to hypoxia is largely
mediated by hypoxia-inducible factor-1 (HIF-1) (Wang
et al. 1995). HIF-1 is a basic helix-loop-helix transcrip-
tion factor composed of a HIF-1β and a HIF-1α, the pro-
duction of which is strongly upregulated under hypoxic
conditions (Acker and Plate 2003). Vascular endothelial
growth factor (VEGF) is a soluble factor that regulates
multiple functions of endothelial cells (Forsythe et al.
1996). Expression of VEGF is rapidly induced by HIF-1
-mediated transcriptional activation in response to low
oxygen levels in vivo as well as in vitro (Acker and Plate
2003; Forsythe et al. 1996). Previous studies haven Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Summary of subjects and their evaluation
parameters
Control OSAS P value
Subject (n) 17 13
Age (years) 44.3 ± 11.3 46.1 ± 12.1 6.79 × 10-1
BMI (kg/m2) 24.9 ± 2.92 29.9 ± 2.60 6.08 × 10-4
AHI 8.03 ± 6.51 50.9 ± 32.5 1.13 × 10-5
SpO2 < 90% (% TST) 0.681 ± 1.31 17.8 ± 16.5 2.84 × 10
-4
4% ODI 4.62 ± 4.23 37.1 ± 23.4 4.82 × 10-6
Median SpO2 (%) 96.4 ± 1.45 93.0 ± 3.08 6.21 × 10
-4
Minimal SpO2 (%) 86.5 ± 6.72 67.6 ± 10.3 1.60 × 10
-6
VEGF (pg/ml) Night 14.8 ± 1.01 12.5 ± 2.24 1.68 × 10-1
Morning 13.0 ± 1.85 10.3 ± 3.09 2.67 × 10-1
bFGF (pg/ml) Night 2.01 ± 0.831 2.21 ± 0.573 7.47 × 10-1
Morning 2.02 ± 0.743 3.43 ± 0.428 7.46 × 10-3
Hb (g/dl) Night 15.2 ± 0.994 14.9 ± 0.953 6.10 × 10-1
Morning 15.4 ± 1.06 15.6 ± 0.875 5.76 × 10-1
All participants were categorized into two groups by their OSAS severity
(control, AHI ≤ 15; and OSAS, 15 < AHI). Concentrations of plasma VEGF, bFGF,
and Hb the night before PSG and the next morning were measured (night and
morning, respectively). Data are presented as mean values ± standard
deviations. Statistical analysis for evaluation parameters among the categories
was performed by the Student t-test.
AHI apnea-hypopnea index, bFGF basic fibroblast growth factor, BMI body
mass index, SpO2 < 90% (% TST) percentage of total sleep time with oxygen
saturation below 90%, Hb hemoglobin, ODI oxygen desaturation index, SpO2
oxygen saturation with pulse oximetry, VEGF vascular endothelial
growth factor.
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elevated in patients with OSAS (Imagawa et al. 2001;
Schulz et al. 2002; Lavie et al. 2002; Gozal et al. 2002).
Basic fibroblast growth factor (bFGF) is also known to
be strongly upregulated by HIF-1 in response to hypoxic
conditions (Calvani et al. 2006). It is recently reported
that bFGF-dependent induction of HIF-1α expression re-
sults in the formation of an HIF-1α-bFGF positive feed-
back amplification pathway under hypoxic conditions in
human umbilical vascular endothelial cells and rat car-
diac microvascular endothelial cells in vitro, although
VEGF, unlike bFGF, does not enhance HIF-1 gene ex-
pression (Calvani et al. 2006; Li et al. 2002). The exist-
ence of an HIF-1α-bFGF autocrine loop suggests that
the systemic level of bFGF, but not VEGF, is likely to be
strongly correlated with the degree of hypoxic state in
OSAS patients. However, thus far no report has demon-
strated the relationship between the severity of OSAS
and levels of bFGF in patients with the disease. Further-
more, a definitive diagnostic marker that is correlated
with the severity of OSAS remains to be identified
(Arnardottir et al. 2009).
Here, we measured the plasma concentrations of
bFGF, VEGF, and Hb in subjects at the night before sleep
and in the next morning immediately after rising, and
we verified the relationship between the degree of
change in the plasma bFGF concentrations before and
after nocturnally recurrent apnea episodes and the sever-
ity of OSAS.Results and discussion
Characteristics of subjects
The characteristics and severity of OSAS in all subjects
are summarized in Table 1. The mean ages of the
two groups were similar, even though body mass index
(BMI) significantly increased in the OSAS group.
Apnea-hypopnea index (AHI), oxygen saturation with
pulse oximetry (SpO2) < 90% (% total sleep time; TST),
4% oxygen desaturation index (ODI), median and min-
imal SpO2, as evaluation parameters of OSAS severity
determined by polysomnography (PSG), significantly dif-
fered between the groups. All of these values were mark-
edly higher or lower in the OSAS group than in the
control group. The concentrations of VEGF and bFGF
in plasma samples at night and the next morning (at
8 p.m. and at 6 a.m., respectively) were measured by
sandwich enzyme-linked immunosorbent assay (ELISA)
(Table 1). Unexpectedly, the plasma levels of VEGF
and Hb did not differ between the groups, regardless
of the morning and the night. However, the plasma
bFGF levels in OSAS patients were significantly higher
than those in control subjects only in the morning but
not at night.Changes in VEGF, bFGF, and Hb after nocturnal apnea
events
To assess changes in the concentrations of plasma
VEGF, bFGF, and Hb after exposure to nocturnal hyp-
oxia, we quantified these soluble factors at the night be-
fore PSG and the next morning after PSG in control and
OSAS groups (Figure 1). In control subjects, the concen-
trations of all the factors were similar before and after
sleep. In contrast, the level of plasma bFGF in the OSAS
group was significantly greater after nocturnal hypoxic
events than before, although there were no significant
changes in VEGF or Hb (Figure 1). The elevation of
plasma bFGF concentrations in OSAS patients was also
confirmed in regression plots of bFGF values measured
before the nigh PSG and the morning after PSG against
AHI (Figure 2). These results imply that plasma levels of
bFGF, unlike those of VEGF and Hb, were affected by
frequent hypoxic exposure through the night in OSAS
patients.
Correlation between overnight change in VEGF and bFGF
and OSAS severity
To evaluate the usefulness of the changes in plasma
VEGF and bFGF levels to predict OSAS severity, we next
investigated the correlation between the overnight














































Figure 1 Changes in concentrations of VEGF, bFGF, and Hb after nocturnal hypoxia. Mean concentrations of plasma VEGF and bFGF, and
Hb values the night before PSG and the next morning after PSG (before PSG, open bars; after PSG, closed bars). All subjects were categorized into
two groups by their OSAS severity (control, AHI≤ 15; and OSAS, 15 < AHI). Statistical analysis was performed by the paired t-test and error bars
show standard deviation.
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associated parameters for severity of OSAS. Statistical
analysis using the Pearson’s correlation coefficient re-
vealed that ΔbFGF, but not ΔVEGF, was positively and
significantly correlated with AHI, SpO2 < 90% (% TST)
and 4% ODI, but neither age nor BMI (Table 2). ΔbFGF
was also negatively and significantly correlated with me-
dian and minimal SpO2. These results suggest that the
change in plasma bFGF might closely reflect the degree
of hypoxia during sleep, i.e., the severity of OSAS.
Discussion
Production of the cytokines VEGF and bFGF is well
known to be induced by hypoxia in a HIF-1-dependent
manner (Forsythe et al. 1996; Calvani et al. 2006). We
therefore hypothesized that plasma levels of these cyto-
kines would be affected by nocturnal hypoxemia in
OSAS patients. We actually indicate that levels of
plasma bFGF, but not VEGF or Hb, are greater in the





Figure 2 Association between bFGF and AHI before and after nocturn
before PSG and the morning after PSG were plotted against AHI.Notably, the change in bFGF, but not VEGF, concentra-
tion after nocturnal apnea episodes was correlated with
AHI, SpO2 < 90% (% TST), 4% ODI, median and min-
imal SpO2. Although we could not demonstrate the role
of bFGF in OSAS patients in this study, and could not
completely exclude the potential cofounders that might
have distributed inequally between control and study
groups, these results raised the possibility that bFGF
might be useful soluble factor for evaluating the severity
of OSAS.
Previous studies have reported that the concentrations
of various soluble factors, including VEGF, Hb, C-
reactive protein, and some inflammatory cytokines in
the serum or plasma, are correlated with AHI (Imagawa
et al. 2001, 2004; Schulz et al. 2002; Lavie et al. 2002;
Gozal et al. 2002; Ohga et al. 2003; Entzian et al. 1996;
Ryan et al. 2005; Yokoe et al. 2003). In particular, VEGF
has been regarded as a potential marker of OSAS
(Lavie et al. 2002). However, the feasibility of using
VEGF has been controversial, partly because there is an (pg/ml)
After PSG
al hypoxia. Concentrations of plasma bFGF measured the night
Table 2 Correlation between ΔVEGF and ΔbFGF, and
OSAS severity
ΔVEGF (pg/ml) ΔbFGF (pg/ml)
rs (P value) rs (P value)
Age (years) −0.202 (1.41 × 10-1) −0.242 (2.04 × 10-1)
BMI (kg/m2) −0.145 (1.20 × 10-1) 0.218 (2.25 × 10-1)
AHI 0.00962 (2.40 × 10-1) 0.371 (1.17 × 10-2)
SpO2 < 90% (% TST) 0.0716 (1.77 × 10
-1) 0.335 (1.88 × 10-2)
4% ODI 0.0126 (2.37 × 10-1) 0.354 (1.48 × 10-2)
Median SpO2 (%) 0.0907 (1.62 × 10
-1) −0.356 (1.69 × 10-2)
Minimal SpO2 (%) −0.0285 (2.20 × 10
-1) −0.314 (1.92 × 10-2)
Correlations between the overnight changes (before and after PSG) in plasma
VEGF and bFGF concentrations (ΔVEGF and ΔbFGF, respectively) and hypoxia-
associated parameters of OSAS severity were analyzed by using the Pearson’s
correlation coefficient. Coefficients of correlation are represented by rs and
statistical probabilities by P values in parentheses.
AHI apnea-hypopnea index, BMI body mass index, bFGF basic fibroblast
growth factor, SpO2 < 90% (% TST) percentage of total sleep time with oxygen
saturation below 90%, ODI oxygen desaturation index, SpO2 oxygen saturation
with pulse oximetry, rs Pearson’s coefficient of correlation, VEGF vascular
endothelial growth factor.
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OSAS patients (Valipour et al. 2004; Peled et al. 2007).
Additionally, the specificity of C-reactive protein and in-
flammatory cytokines (e.g. tumor necrosis factor-α and
interleukin-6) for OSAS seems to be low because of the
high basal levels of these substances in patients with
inflammatory disease, autoimmune disease, and many
other diseases (Sharma et al. 2008; Dinarello 1991;
Feldmann and Maini 2001; Ishihara and Hirano 2002).
This is despite the finding that comprehensive measure-
ment of multiple cytokines has shown high levels of
agreement with the AHI and may help in the diagnosis
of OSAS severity (Li et al. 2009).
In contrast, only a few reports have demonstrated cor-
relations between levels of bFGF and some diseases, not
including OSAS; positive correlations have been found
with severe limb ischemia and specific kinds of tumors
(Rohovsky et al. 1996; Fujita et al. 1996; Clarke et al.
1998). We hypothesized that bFGF was strongly associ-
ated with the hypoxic condition in patients with OSAS,
as suggested by the formation of a bFGF-HIF-1α amplifi-
cation loop (Calvani et al. 2006). In the patients, vascular
endothelial cells are readily speculated to be the major
source of bFGF during nocturnal hypoxia, which is a
situation similar to that of upregulation of bFGF in vas-
cular endothelial cells after the hypoxic exposure in vitro
(Calvani et al. 2006; Li et al. 2002). bFGF is shown to
mediate a strong angiogenic activity through induction
of proliferation of vascular endothelial cells as well as
migration of inflammatory cells, perithelial cells, and
smooth muscle cells (Calvani et al. 2006; Li et al. 2002;
Ruel and Sellke 2003). Therefore, bFGF is one of the
feasible target molecules for therapy for ischemic heartdiseases including chronic myocardial ischemia, coron-
ary sclerosis, and myocardial infarction (Ruel and Sellke
2003; Hammond and McKirnan 2001). In fact, bFGF is
reported to have a therapeutic effect in clinical trials in
coronary angiogenesis and in animal models of an ische-
mic heart disease and critical limb ischemia (Nakajima
et al. 2004; Hammond and McKirnan 2001; Simons
et al. 2000). On the other hand, bFGF has a hypotensive
activity (Cuevas et al. 1991). Taken together, the eleva-
tion of systemic levels of bFGF after hypoxic exposure in
OSAS patients is primarily supposed to have a patho-
physiological role for protection of exacerbated compli-
cations of OSAS, e.g. coronary sclerosis, hypertension,
ischemic heart diseases. We observed that the change of
bFGF concentrations reflected the hypoxic condition in
patients with OSAS during sleep periods. Moreover, our
results showed the significant relevance between the
change in bFGF after nocturnal hypoxic events and diag-
nostic parameters for OSAS severity, suggesting that it
would be worth validating the clinical usefulness of
bFGF. In light of our relatively small sample size, further
studies of larger numbers of subjects, including OSAS
patients treated by nasal continuous positive air pres-
sure, are required to validate the reliability of bFGF as a
diagnostic marker of OSAS in the clinical arena.
Conclusions
We suggested that levels of plasma bFGF were greater in
the morning than at the night before in patients with
OSAS. The change in bFGF concentration after noctur-
nal apnea episodes was associated with the degree of
hypoxic state in OSAS patients. These results raise the
possibility that bFGF might be useful soluble factor for
evaluating the severity of OSAS.
Methods
Subjects
Thirty male subjects who were suspected OSAS at the
Division of Sleep Medicine participated in this study at
the Tsukuba University Hospital. Male subjects with cor-
onary artery disease, hypertension, chronic obstructive
pulmonary disease, and inflammatory diseases, and fe-
male subjects were excluded in this study, because the
basal levels of their plasma bFGF and VEGF might be
affected by inflammation, female sex hormones, and
menopausal status. All subjects with suspected OSAS
were enrolled in this study and were categorized by their
AHI values (control, AHI < 15; and OSAS, 15 < AHI)
(Table 1). All subjects provided written informed con-
sent after receiving a full explanation of the procedures.
This study was approved by the University of Tsukuba
institutional review committee and was performed in
accordance with the recommendations found in the
Helsinki Declaration.
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height (m) squared.
PSG
The sleep and respiratory evaluations of all participants
were manually scored by specialists at the Division of
Sleep Medicine, Tsukuba University Hospital. All sub-
jects underwent a standard overnight PSG with comput-
erized recording by the Alice-5 system (Respironics;
Pittsburgh, PA). Recordings included an electroenceph-
alogram (at positions C3/A2, C4/A1, O1/A2, and O2/A1
of the International 10–20 System), electrooculogram,
submental electromyogram, left and right tibialis anter-
ior electromyogram, thoracic-abdominal effort, oral/
nasal airflow (thermistor- and pressure-based flow meas-
urement), SpO2, and body position. Scoring of sleep
stage and respiratory events were based on the criteria
of the American Academy of Sleep Medicine (Iber et al.
2007). Apnea was defined as the cessation of inspiration
for no less than 10 seconds. Hypopnea was defined as a
reduction in airflow by no less than 30%, with a decrease
in SpO2 by 4% or more, for at least 10 seconds in the
presence of thoracoabdominal ventilatory effort. Ob-
structive apnea was defined as the absence of airflow in
the presence of ribcage or abdominal excursions. The
AHI was calculated as the total number of apneic and
hypopneic events per hour of sleep periods. All such
events were counted, irrespective of the occurrence of
arousal that was defined according the criteria of the
American Sleep Disorders Association (1992). TST was
defined as the time from the first to last recorded sleep
periods, excluding wakefulness. The 4% ODI was defined
as the total number of 4% desaturation of oxyhemoglo-
bin divided by TST and was expressed as the number of
events per hour. The percentage of the TST with SpO2
below 90% (SpO2 < 90% (% TST)) was also measured.
An AHI of more than 15, irrespective of the presence of
sleep-related symptoms (i.e. snoring, witnessed apnea,
excessive daytime sleepiness), was considered as diag-
nostic of OSAS.
Measurement of VEGF and bFGF in plasma
At the night before the PSG and in the next morning
after the subject arose (at 8 p.m. and at 6 a.m., respect-
ively), peripheral blood was carefully collected into tubes
with buffered citrate. Plasma samples were prepared by
centrifugation at 1500 rpm for 10 minutes at 20°C
followed by collection of the supernatants. The superna-
tants were frozen at −80°C immediately after the collec-
tion in order to avoid degradation of soluble factors in
them. The concentrations of plasma VEGF and bFGF
were determined by sandwich ELISA with quantitative
ELISA kits (R&D, Minneapolis, MN). The change in the
plasma VEGF and bFGF concentrations from the nightof the PSG to the next morning after rising was de-
scribed as ΔVEGF and ΔbFGF, respectively.
Statistical analysis
Statistical analysis for evaluation parameters among cat-
egories of subjects (age, BMI, AHI, SpO2 < 90% (% TST),
4% ODI, median and minimal SpO2, and plasma VEGF,
bFGF, and Hb concentrations the night before PSG and
the next morning) was performed by the Student t-test.
Statistical analysis for concentrations of plasma VEGF,
bFGF, and Hb before and after sleep was performed by
the paired t-test. P < 0.05 is regarded as a statistically
significant difference. Statistical power analysis was
performed by a G*Power 3 program (Heinrich-Heine-
Universität). The correlation between ΔVEGF and
ΔbFGF, and AHI, SpO2 < 90% (% TST), 4% ODI, median
and minimal SpO2 in each subject was evaluated with
the Pearson’s correlation coefficient.
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